---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-022774"
form_type: "8-K"
ticker: "IDXG"
cik: "0001054102"
company_name: "INTERPACE BIOSCIENCES, INC."
filed_at: "2025-08-08T23:59:59+00:00"
generated_at: "2026-05-17T16:05:22.266074+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Interpace Biosciences Q2 revenue down 23% to $9.2M; loss from continuing ops $0.5M

## Summary
- Net revenue $9.2M (-23% YoY); loss from continuing ops $0.5M vs income $2.5M a year ago.
- Thyroid test volume up 16% YoY; thyroid revenue $8.7M (+25% YoY) to record levels.
- Gross margin 57% (65% ex one-time PancraGEN impact); adjusted EBITDA $0.4M vs $2.8M.
- One-time charge $1.2M from PancraGEN reimbursement loss; company winding down test.
- Preliminary July 2025 revenue $3.3M (+54% YoY); management sees Q3 improvement.

## SEC filing metadata
- accession: 0001641172-25-022774
- form_type: 8-K
- ticker: IDXG
- cik: 0001054102
- company_name: INTERPACE BIOSCIENCES, INC.
- filed_at: 2025-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1054102/000164117225022774/0001641172-25-022774-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1054102/000164117225022774/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-022774
- JSON: https://secwatch.observer/filing/0001641172-25-022774.json
- Plain text: https://secwatch.observer/filing/0001641172-25-022774.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.